blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3256495

EP3256495 - COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.08.2019
Database last updated on 13.09.2024
FormerRequest for examination was made
Status updated on  17.11.2017
FormerThe international publication has been made
Status updated on  04.09.2017
Most recent event   Tooltip30.08.2019Application deemed to be withdrawnpublished on 02.10.2019  [2019/40]
Applicant(s)For all designated states
Aptevo Research and Development LLC
2401 Fourth Avenue
Suite 1050
Seattle, Washington 98121 / US
[2017/51]
Inventor(s)01 / BLANKENSHIP, John
c/o EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC
2401 Fourth Ave.
Suite 1050
Seattle, Washington 98121 / US
02 / SEWELL, Elaine Todd
c/o EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC
2401 Fourth Ave.
Suite 1050
Seattle, Washington 98121 / US
 [2017/51]
Representative(s)Walker, Ross Thomson
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[2017/51]
Application number, filing date16749890.611.02.2016
[2017/51]
WO2016US17568
Priority number, dateUS201562114871P11.02.2015         Original published format: US 201562114871 P
[2017/51]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016130819
Date:18.08.2016
Language:EN
[2016/33]
Type: A2 Application without search report 
No.:EP3256495
Date:20.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 18.08.2016 takes the place of the publication of the European patent application.
[2017/51]
Search report(s)International search report - published on:US29.09.2016
(Supplementary) European search report - dispatched on:EP21.08.2018
ClassificationIPC:C07K16/40, C07K16/30, A61K39/395, C07K16/28, A61K45/06, A61K31/58, A61K31/496, A61K31/4439, A61K31/4188, A61K31/4166, A61K39/00, A61P35/00
[2018/38]
CPC:
C07K16/3069 (EP,US); A61K31/4166 (EP,US); A61K31/4188 (EP,US);
A61K31/4439 (EP,US); A61K31/496 (EP,US); A61K31/58 (EP,US);
A61K39/39558 (US); A61K45/06 (EP,US); A61P35/00 (EP,US);
C07K16/2809 (EP,US); A61K2039/505 (US); C07K2317/24 (US);
C07K2317/31 (EP,US); C07K2317/522 (US); C07K2317/53 (US);
C07K2317/565 (US); C07K2317/622 (US); C07K2317/73 (EP,US) (-)
C-Set:
A61K31/4166, A61K2300/00 (EP,US);
A61K31/4188, A61K2300/00 (US,EP);
A61K31/4439, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP);
A61K31/58, A61K2300/00 (US,EP)
(-)
Former IPC [2017/51]C07K16/40, C07K16/30, A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/51]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR KOMBINATIONSTHERAPIE MIT PROSTATASPEZIFISCHEN MEMBRANANTIGENBINDENDEN PROTEINEN[2017/51]
English:COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS[2017/51]
French:COMPOSITIONS ET MÉTHODES DE POLYTHÉRAPIE COMBINÉES À DES PROTÉINES SE LIANT À L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE[2017/51]
Entry into regional phase04.09.2017National basic fee paid 
05.09.2017Search fee paid 
04.09.2017Designation fee(s) paid 
04.09.2017Examination fee paid 
Examination procedure04.09.2017Examination requested  [2017/51]
04.09.2017Date on which the examining division has become responsible
06.04.2018Amendment by applicant (claims and/or description)
19.03.2019Application deemed to be withdrawn, date of legal effect  [2019/40]
08.05.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2019/40]
Fees paidRenewal fee
31.01.2018Renewal fee patent year 03
13.02.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]US2014099257  (BANDER NEIL H [US]) [X] 1-4,7-9,12-14 * abstract * * paragraphs [0012] - [0014] - [0038] - [0040] * [I] 5,6,10,11,15;
 [XI]US2004120958  (BANDER NEIL H [US], et al) [X] 1-4,7-9,12-14 * abstract * * paragraphs [0017] , [0018] , [0175] * [I] 5,6,10,11,15;
 [XI]WO2006110745  (CYTOGEN CORP [US], et al) [X] 1-4,7-9,12-14 * abstract * * page 8, line 12 - line 28 * * page 15, line 31 - page 16, line 12 * [I] 5,6,10,11,15
 [XI]  - JOSE D. MURGA ET AL, "Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer", PROSTATE., US, (20141018), vol. 75, no. 3, doi:10.1002/pros.22910, ISSN 0270-4137, pages 242 - 254, XP055259705 [X] 1-4,7-9,12-14 * abstract * * Conclusions * [I] 5,6,10,11,15

DOI:   http://dx.doi.org/10.1002/pros.22910
International search[XY]WO2009046294  (UNIV CORNELL [US], et al) [X] 1-3, 46, 47, 59-61, 64/59-61, 67 * ; paragraphs [0078], [00109], [00104], [00106], [00108], [00111]; claim 1 * [Y] 4-8, 9/7-8, 10/9/7-8, 23, 24, 26-30, 33-35, 36/33-35, 37-39, 41, 43, 49/43, 53/43, 54/53/43, 62, 63, 64/62-63, 68-69, 70/67-69, 73;
 [Y]US2014161800  (BLANKENSHIP JOHN W [US], et al) [Y] 4-8, 9/7-8, 10/9/7-8, 23, 24, 26-30, 33-35, 36/33-35, 37-39, 43, 49/43, 53/43, 54/53/43, 70/67-69, 73 * ; Figure 2A; paragraphs [0009]-[0015], [0023], [0025], [0029]-[0033], [0037], [0045], [0046], [0049], [0074], [0110], [0122], [0123], [0134], [0248], [0251]; pages 77-79; Claim 186 *;
 [Y]WO2010037836  (MICROMET AG [DE], et al) [Y] 41 * ; Claim 11 *;
 [Y]WO2014043208  (MEDIVATION PROSTATE THERAPEUTICS INC [US], et al) [Y] 62, 64/62, 69, 70/69 * ; paragraph [15] *;
 [Y]  - STEIN, MN et al., "Androgen Synthesis Inhibitors in the Treatment of Castration-Resistant Prostate Cancer.", Asian Journal of Andrology., (20100418), vol. 16, pages 387 - 400, XP055316057 [Y] 68 * ; abstract. DOI: 10.4103/1008-682X.129133 *

DOI:   http://dx.doi.org/10.4103/1008-682X.129133
 [Y]  - CRAWFORD, ED et al., "The Role of LHRH Antagonists in the Treatment of Prostate Cancer.", Oncology., (20090600), vol. 23, no. 7, pages 662 - 630, XP055316059 [Y] 64/59-63 * ; page 2, second paragraph *
 [Y]  - CHAKRAVARTY, D et al., "The Oestrogen Receptor Alpha-Regulated IncRNA NEAT1 is a Critical Modulator of Prostate Cancer.", Nature Communications., (20141121), vol. 5, no. 5383, XP055231010 [Y] 63, 64/63 * ; figure 1; page 2, second column, second paragraph. DOI: 10.1038/ncomms6383 *

DOI:   http://dx.doi.org/10.1038/ncomms6383
 [Y]  - CHOU, TC, "Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method.", Cancer Research, (20100115), vol. 70, no. 2, pages 440 - 446, XP055169871 [Y] 73 * ; abstract. DOI: 10.1158/0008-5472 *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.